Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5 '-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (Pki-587), A Highly Efficacious Dual Inhibitor
Aranapakam M. Venkatesan,Christoph M. Dehnhardt,Efren Delos Santos,Zecheng Chen,Osvaldo Dos Santos,Semiramis Ayral-Kaloustian,Gulnaz Khafizova,Natasja Brooijmans,Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Ker Yu,James Gibbons,Robert T. Abraham,Inder Chaudhary,Tarek S. Mansour
DOI: https://doi.org/10.1021/jm901830p
IF: 8.039
2010-01-01
Journal of Medicinal Chemistry
Abstract:The PI3K/Akt signaling pathway is a key pathway in cell proliferation, growth, survival, protein synthesis, and glucose metabolism. It has been recognized recently that inhibiting this pathway might provide a viable therapy for cancer. A series of bis(morpholino-1,3,5-triazine) derivatives were prepared and optimized to provide the highly efficacious PI3K/mTOR inhibitor 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 26 (PKI-587). Compound 26 has shown excellent activity in vitro and in vivo, with antitumor efficacy in both subcutaneous and orthotopic xenograft tumor models when administered intravenously. The structure activity relationships and the in vitro and in vivo activity of analogues in this series arc described.